Loading…
Whole abdominal field versus standard field radiotherapy plus concomitant and adjuvant chemotherapy for patients with locally advanced gastric cancer
To compare standard radiotherapy field (SRTF) with whole abdomen irradiation (WAI), used in conjunction with adjuvant chemotherapy following curative surgery in patients with gastric cancer. Ninety patients were included in the study and divided into two treatment arms. In the first treatment arm, S...
Saved in:
Published in: | Journal of radiation research 2011, Vol.52 (2), p.168-175 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c402t-c18e09016696a7da8cc3d31eb3c42cd11063e609081ef90e6fdb10242027b2a33 |
---|---|
cites | cdi_FETCH-LOGICAL-c402t-c18e09016696a7da8cc3d31eb3c42cd11063e609081ef90e6fdb10242027b2a33 |
container_end_page | 175 |
container_issue | 2 |
container_start_page | 168 |
container_title | Journal of radiation research |
container_volume | 52 |
creator | Orhan, Okan Eroglu, Celalettin Kaplan, Bünyamin Ucar, Kadir Altinbas, Mustafa Ozkan, Metin Unal, Dilek Yildiz, Oğuz Galip Soyuer, Serdar |
description | To compare standard radiotherapy field (SRTF) with whole abdomen irradiation (WAI), used in conjunction with adjuvant chemotherapy following curative surgery in patients with gastric cancer.
Ninety patients were included in the study and divided into two treatment arms. In the first treatment arm, SRTF, including 45 Gy radiation to the primary tumor and regional lymph nodes, was performed in 45 patients. In the second treatment arm, a total of 45.2 Gy RT was delivered; 20 Gy to the whole abdomen followed by 25.2 Gy RT to the tumor and regional lymph nodes, in 45 patients. An intravenous bolus dose of 250 mg/m(2)/week 5-fluorouracil (5-FU) was administered concomitantly with RT in both treatment arms. Patients who completed concomitant chemoradiotherapy, received adjuvant treatment, including 4 cycles of 5-FU (425 mg/m(2)) and folinic acid (20 mg/m(2)) in 4 week intervals.
Median age was 56 years (range: 22-81), 89% of the patients (n = 80) had serosal involvement, 78% (n = 70) were node positive. The rate of hematological (40% vs. 16%, p = 0.010) and gastrointestinal toxicities (80% vs. 53%, p = 0.010) were higher, and performance loss (60% vs. 29%, p = 0.003) was greater in the second treatment arm. Number of patients who experienced Grade 3 and Grade 4 gastrointestinal toxicities (especially diarrhea) were higher in the second treatment arm (4% vs. 16%, p = 0.049). The median follow-up was 19 months (range: 7-96). The median 5-year survival was 29% and 17%, locoregional control was 30% and 25%, and disease-free survival was 27% and 16% in the first and second treatment arms, respectively. There was no significant difference between the treatment groups in terms of survival, locoregional control and disease-free survival rates (p > 0.05).
Whole abdomen irradiation was not found to be superior to standard field radiotherapy used in conjunction with adjuvant chemotherapy in gastric cancer. |
doi_str_mv | 10.1269/jrr.10075 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_858781916</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3108678501</sourcerecordid><originalsourceid>FETCH-LOGICAL-c402t-c18e09016696a7da8cc3d31eb3c42cd11063e609081ef90e6fdb10242027b2a33</originalsourceid><addsrcrecordid>eNpd0b1u2zAUBWCiSFA7boe-QEEgQ5HB7iUpUdIYGM0PEKBLgo4CRV7VMihRIakEfpC-b-ja8ZCJvMTHO5xDyDcGK8Zl9XPr_YoBFPknMmciq5YVy4szMocs3QVImJGLELYAvIAcPpMZT0rIks_Jvz8bZ5Gqxri-G5SlbYfW0Bf0YQo0RDUY5c3x1SvTubhBr8YdHW0C2g06fUws0kSpMtvpZT_oDfYn2jpPRxU7HGKgr13cUOu0snaXfNIaDf2rQvSdpno_-i_kvFU24NfjuSBPN78e13fLh9-39-vrh6XOgMelZiVCBUzKSqrCqFJrYQTDRuiMa8MYSIEyiZJhWwHK1jQMeMZTEA1XQizIj8Pe0bvnCUOs-y5otFYN6KZQl3lZlKxiMsnLD3LrJp8CCzXLUsw5VGKvrg5KexeCx7Yefdcrv6sZ1Puq6lRV_b-qZL8fN05Nj-Yk37sRb3ITkbQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1444950936</pqid></control><display><type>article</type><title>Whole abdominal field versus standard field radiotherapy plus concomitant and adjuvant chemotherapy for patients with locally advanced gastric cancer</title><source>J-STAGE (Japan Science & Technology Information Aggregator, Electronic) - Open Access English articles</source><source>Open Access: Oxford University Press Open Journals</source><creator>Orhan, Okan ; Eroglu, Celalettin ; Kaplan, Bünyamin ; Ucar, Kadir ; Altinbas, Mustafa ; Ozkan, Metin ; Unal, Dilek ; Yildiz, Oğuz Galip ; Soyuer, Serdar</creator><creatorcontrib>Orhan, Okan ; Eroglu, Celalettin ; Kaplan, Bünyamin ; Ucar, Kadir ; Altinbas, Mustafa ; Ozkan, Metin ; Unal, Dilek ; Yildiz, Oğuz Galip ; Soyuer, Serdar</creatorcontrib><description>To compare standard radiotherapy field (SRTF) with whole abdomen irradiation (WAI), used in conjunction with adjuvant chemotherapy following curative surgery in patients with gastric cancer.
Ninety patients were included in the study and divided into two treatment arms. In the first treatment arm, SRTF, including 45 Gy radiation to the primary tumor and regional lymph nodes, was performed in 45 patients. In the second treatment arm, a total of 45.2 Gy RT was delivered; 20 Gy to the whole abdomen followed by 25.2 Gy RT to the tumor and regional lymph nodes, in 45 patients. An intravenous bolus dose of 250 mg/m(2)/week 5-fluorouracil (5-FU) was administered concomitantly with RT in both treatment arms. Patients who completed concomitant chemoradiotherapy, received adjuvant treatment, including 4 cycles of 5-FU (425 mg/m(2)) and folinic acid (20 mg/m(2)) in 4 week intervals.
Median age was 56 years (range: 22-81), 89% of the patients (n = 80) had serosal involvement, 78% (n = 70) were node positive. The rate of hematological (40% vs. 16%, p = 0.010) and gastrointestinal toxicities (80% vs. 53%, p = 0.010) were higher, and performance loss (60% vs. 29%, p = 0.003) was greater in the second treatment arm. Number of patients who experienced Grade 3 and Grade 4 gastrointestinal toxicities (especially diarrhea) were higher in the second treatment arm (4% vs. 16%, p = 0.049). The median follow-up was 19 months (range: 7-96). The median 5-year survival was 29% and 17%, locoregional control was 30% and 25%, and disease-free survival was 27% and 16% in the first and second treatment arms, respectively. There was no significant difference between the treatment groups in terms of survival, locoregional control and disease-free survival rates (p > 0.05).
Whole abdomen irradiation was not found to be superior to standard field radiotherapy used in conjunction with adjuvant chemotherapy in gastric cancer.</description><identifier>ISSN: 0449-3060</identifier><identifier>EISSN: 1349-9157</identifier><identifier>DOI: 10.1269/jrr.10075</identifier><identifier>PMID: 21343682</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Abdomen - radiation effects ; Adult ; Aged ; Aged, 80 and over ; Chemotherapy, Adjuvant - methods ; Combined Modality Therapy - methods ; Disease-Free Survival ; Female ; Fluorouracil - pharmacology ; Follow-Up Studies ; Gastrectomy - methods ; Humans ; Male ; Middle Aged ; Radiotherapy - methods ; Radiotherapy, Adjuvant - methods ; Recurrence ; Stomach Neoplasms - drug therapy ; Stomach Neoplasms - radiotherapy ; Treatment Outcome</subject><ispartof>Journal of radiation research, 2011, Vol.52 (2), p.168-175</ispartof><rights>Copyright Japan Science and Technology Agency 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c402t-c18e09016696a7da8cc3d31eb3c42cd11063e609081ef90e6fdb10242027b2a33</citedby><cites>FETCH-LOGICAL-c402t-c18e09016696a7da8cc3d31eb3c42cd11063e609081ef90e6fdb10242027b2a33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4022,27922,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21343682$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Orhan, Okan</creatorcontrib><creatorcontrib>Eroglu, Celalettin</creatorcontrib><creatorcontrib>Kaplan, Bünyamin</creatorcontrib><creatorcontrib>Ucar, Kadir</creatorcontrib><creatorcontrib>Altinbas, Mustafa</creatorcontrib><creatorcontrib>Ozkan, Metin</creatorcontrib><creatorcontrib>Unal, Dilek</creatorcontrib><creatorcontrib>Yildiz, Oğuz Galip</creatorcontrib><creatorcontrib>Soyuer, Serdar</creatorcontrib><title>Whole abdominal field versus standard field radiotherapy plus concomitant and adjuvant chemotherapy for patients with locally advanced gastric cancer</title><title>Journal of radiation research</title><addtitle>J Radiat Res</addtitle><description>To compare standard radiotherapy field (SRTF) with whole abdomen irradiation (WAI), used in conjunction with adjuvant chemotherapy following curative surgery in patients with gastric cancer.
Ninety patients were included in the study and divided into two treatment arms. In the first treatment arm, SRTF, including 45 Gy radiation to the primary tumor and regional lymph nodes, was performed in 45 patients. In the second treatment arm, a total of 45.2 Gy RT was delivered; 20 Gy to the whole abdomen followed by 25.2 Gy RT to the tumor and regional lymph nodes, in 45 patients. An intravenous bolus dose of 250 mg/m(2)/week 5-fluorouracil (5-FU) was administered concomitantly with RT in both treatment arms. Patients who completed concomitant chemoradiotherapy, received adjuvant treatment, including 4 cycles of 5-FU (425 mg/m(2)) and folinic acid (20 mg/m(2)) in 4 week intervals.
Median age was 56 years (range: 22-81), 89% of the patients (n = 80) had serosal involvement, 78% (n = 70) were node positive. The rate of hematological (40% vs. 16%, p = 0.010) and gastrointestinal toxicities (80% vs. 53%, p = 0.010) were higher, and performance loss (60% vs. 29%, p = 0.003) was greater in the second treatment arm. Number of patients who experienced Grade 3 and Grade 4 gastrointestinal toxicities (especially diarrhea) were higher in the second treatment arm (4% vs. 16%, p = 0.049). The median follow-up was 19 months (range: 7-96). The median 5-year survival was 29% and 17%, locoregional control was 30% and 25%, and disease-free survival was 27% and 16% in the first and second treatment arms, respectively. There was no significant difference between the treatment groups in terms of survival, locoregional control and disease-free survival rates (p > 0.05).
Whole abdomen irradiation was not found to be superior to standard field radiotherapy used in conjunction with adjuvant chemotherapy in gastric cancer.</description><subject>Abdomen - radiation effects</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Chemotherapy, Adjuvant - methods</subject><subject>Combined Modality Therapy - methods</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Fluorouracil - pharmacology</subject><subject>Follow-Up Studies</subject><subject>Gastrectomy - methods</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Radiotherapy - methods</subject><subject>Radiotherapy, Adjuvant - methods</subject><subject>Recurrence</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>Stomach Neoplasms - radiotherapy</subject><subject>Treatment Outcome</subject><issn>0449-3060</issn><issn>1349-9157</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNpd0b1u2zAUBWCiSFA7boe-QEEgQ5HB7iUpUdIYGM0PEKBLgo4CRV7VMihRIakEfpC-b-ja8ZCJvMTHO5xDyDcGK8Zl9XPr_YoBFPknMmciq5YVy4szMocs3QVImJGLELYAvIAcPpMZT0rIks_Jvz8bZ5Gqxri-G5SlbYfW0Bf0YQo0RDUY5c3x1SvTubhBr8YdHW0C2g06fUws0kSpMtvpZT_oDfYn2jpPRxU7HGKgr13cUOu0snaXfNIaDf2rQvSdpno_-i_kvFU24NfjuSBPN78e13fLh9-39-vrh6XOgMelZiVCBUzKSqrCqFJrYQTDRuiMa8MYSIEyiZJhWwHK1jQMeMZTEA1XQizIj8Pe0bvnCUOs-y5otFYN6KZQl3lZlKxiMsnLD3LrJp8CCzXLUsw5VGKvrg5KexeCx7Yefdcrv6sZ1Puq6lRV_b-qZL8fN05Nj-Yk37sRb3ITkbQ</recordid><startdate>2011</startdate><enddate>2011</enddate><creator>Orhan, Okan</creator><creator>Eroglu, Celalettin</creator><creator>Kaplan, Bünyamin</creator><creator>Ucar, Kadir</creator><creator>Altinbas, Mustafa</creator><creator>Ozkan, Metin</creator><creator>Unal, Dilek</creator><creator>Yildiz, Oğuz Galip</creator><creator>Soyuer, Serdar</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>2011</creationdate><title>Whole abdominal field versus standard field radiotherapy plus concomitant and adjuvant chemotherapy for patients with locally advanced gastric cancer</title><author>Orhan, Okan ; Eroglu, Celalettin ; Kaplan, Bünyamin ; Ucar, Kadir ; Altinbas, Mustafa ; Ozkan, Metin ; Unal, Dilek ; Yildiz, Oğuz Galip ; Soyuer, Serdar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c402t-c18e09016696a7da8cc3d31eb3c42cd11063e609081ef90e6fdb10242027b2a33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Abdomen - radiation effects</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Chemotherapy, Adjuvant - methods</topic><topic>Combined Modality Therapy - methods</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Fluorouracil - pharmacology</topic><topic>Follow-Up Studies</topic><topic>Gastrectomy - methods</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Radiotherapy - methods</topic><topic>Radiotherapy, Adjuvant - methods</topic><topic>Recurrence</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>Stomach Neoplasms - radiotherapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Orhan, Okan</creatorcontrib><creatorcontrib>Eroglu, Celalettin</creatorcontrib><creatorcontrib>Kaplan, Bünyamin</creatorcontrib><creatorcontrib>Ucar, Kadir</creatorcontrib><creatorcontrib>Altinbas, Mustafa</creatorcontrib><creatorcontrib>Ozkan, Metin</creatorcontrib><creatorcontrib>Unal, Dilek</creatorcontrib><creatorcontrib>Yildiz, Oğuz Galip</creatorcontrib><creatorcontrib>Soyuer, Serdar</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of radiation research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Orhan, Okan</au><au>Eroglu, Celalettin</au><au>Kaplan, Bünyamin</au><au>Ucar, Kadir</au><au>Altinbas, Mustafa</au><au>Ozkan, Metin</au><au>Unal, Dilek</au><au>Yildiz, Oğuz Galip</au><au>Soyuer, Serdar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Whole abdominal field versus standard field radiotherapy plus concomitant and adjuvant chemotherapy for patients with locally advanced gastric cancer</atitle><jtitle>Journal of radiation research</jtitle><addtitle>J Radiat Res</addtitle><date>2011</date><risdate>2011</risdate><volume>52</volume><issue>2</issue><spage>168</spage><epage>175</epage><pages>168-175</pages><issn>0449-3060</issn><eissn>1349-9157</eissn><abstract>To compare standard radiotherapy field (SRTF) with whole abdomen irradiation (WAI), used in conjunction with adjuvant chemotherapy following curative surgery in patients with gastric cancer.
Ninety patients were included in the study and divided into two treatment arms. In the first treatment arm, SRTF, including 45 Gy radiation to the primary tumor and regional lymph nodes, was performed in 45 patients. In the second treatment arm, a total of 45.2 Gy RT was delivered; 20 Gy to the whole abdomen followed by 25.2 Gy RT to the tumor and regional lymph nodes, in 45 patients. An intravenous bolus dose of 250 mg/m(2)/week 5-fluorouracil (5-FU) was administered concomitantly with RT in both treatment arms. Patients who completed concomitant chemoradiotherapy, received adjuvant treatment, including 4 cycles of 5-FU (425 mg/m(2)) and folinic acid (20 mg/m(2)) in 4 week intervals.
Median age was 56 years (range: 22-81), 89% of the patients (n = 80) had serosal involvement, 78% (n = 70) were node positive. The rate of hematological (40% vs. 16%, p = 0.010) and gastrointestinal toxicities (80% vs. 53%, p = 0.010) were higher, and performance loss (60% vs. 29%, p = 0.003) was greater in the second treatment arm. Number of patients who experienced Grade 3 and Grade 4 gastrointestinal toxicities (especially diarrhea) were higher in the second treatment arm (4% vs. 16%, p = 0.049). The median follow-up was 19 months (range: 7-96). The median 5-year survival was 29% and 17%, locoregional control was 30% and 25%, and disease-free survival was 27% and 16% in the first and second treatment arms, respectively. There was no significant difference between the treatment groups in terms of survival, locoregional control and disease-free survival rates (p > 0.05).
Whole abdomen irradiation was not found to be superior to standard field radiotherapy used in conjunction with adjuvant chemotherapy in gastric cancer.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>21343682</pmid><doi>10.1269/jrr.10075</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0449-3060 |
ispartof | Journal of radiation research, 2011, Vol.52 (2), p.168-175 |
issn | 0449-3060 1349-9157 |
language | eng |
recordid | cdi_proquest_miscellaneous_858781916 |
source | J-STAGE (Japan Science & Technology Information Aggregator, Electronic) - Open Access English articles; Open Access: Oxford University Press Open Journals |
subjects | Abdomen - radiation effects Adult Aged Aged, 80 and over Chemotherapy, Adjuvant - methods Combined Modality Therapy - methods Disease-Free Survival Female Fluorouracil - pharmacology Follow-Up Studies Gastrectomy - methods Humans Male Middle Aged Radiotherapy - methods Radiotherapy, Adjuvant - methods Recurrence Stomach Neoplasms - drug therapy Stomach Neoplasms - radiotherapy Treatment Outcome |
title | Whole abdominal field versus standard field radiotherapy plus concomitant and adjuvant chemotherapy for patients with locally advanced gastric cancer |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T06%3A43%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Whole%20abdominal%20field%20versus%20standard%20field%20radiotherapy%20plus%20concomitant%20and%20adjuvant%20chemotherapy%20for%20patients%20with%20locally%20advanced%20gastric%20cancer&rft.jtitle=Journal%20of%20radiation%20research&rft.au=Orhan,%20Okan&rft.date=2011&rft.volume=52&rft.issue=2&rft.spage=168&rft.epage=175&rft.pages=168-175&rft.issn=0449-3060&rft.eissn=1349-9157&rft_id=info:doi/10.1269/jrr.10075&rft_dat=%3Cproquest_cross%3E3108678501%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c402t-c18e09016696a7da8cc3d31eb3c42cd11063e609081ef90e6fdb10242027b2a33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1444950936&rft_id=info:pmid/21343682&rfr_iscdi=true |